Contineum Therapeutics (CTNM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Contineum Therapeutics (CTNM) is Moderate Underperform.

The composite score behind that read is -0.33, weighing +0.08 of bullish evidence against -0.41 bearish.

Contineum Therapeutics last closed at $12.72, -3.05% on the session.

Against the IVW growth benchmark the position is -3.97% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

10 graded predictions for CTNM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Contineum Therapeutics in the 25th percentile on return on equity, where 100 is best.

Contineum Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $493.59M.

StockMap tracks Contineum Therapeutics as the 67th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite Contineum Therapeutics ranks 81st of 128 in the group, against a group median of -0.24.